Fig. 4: The serum immune proteomics are associated with prognosis and treatment efficacy. | Nature Communications

Fig. 4: The serum immune proteomics are associated with prognosis and treatment efficacy.

From: Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial

Fig. 4

A, B Comparison of pretreatment serum protein levels in responders and non-responders (responder n = 22; non-responder n = 7). C The expressive level of some serum protein could predict survival time (n = 29). D Changes of serum protein expression levels before and after disease progression (n = 5 individuals). For paired samples, if the difference between the two samples met normality, a paired t-test was used. If the difference did not meet normality, the Wilcoxon Signed-Rank Test was applied. All tests were two-sided for statistical evaluation. No adjustments for multiple comparisons were made. Each box plot shows the median as the central line, with the box boundaries representing the first and third quartiles (25th and 75th percentiles), and the whiskers indicating the range from minimum to maximum values. Source data are provided as a Source Data file.

Back to article page